Mesalazine

Mesalazine releases 5‑aminosalicylic acid in the colon where it blocks cyclooxygenase and lipoxygenase enzymes, lowering prostaglandin and leukotriene production. It also modulates cytokine release and neutrophil activity, providing a targeted anti‑inflammatory effect.

The exact dose and frequency of Mesalazine are determined by the prescribing clinician based on the severity of disease, patient weight, and response to therapy. Dosage instructions are provided on the prescription label.

Safety data for Mesalazine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers must weigh potential benefits against possible risks before prescribing to pregnant or nursing patients.

To request Mesalazine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mesalazine is a 5‑ASA agent similar to sulfasalazine and olsalazine but is delivered rectally, providing higher local concentrations in the distal colon. This can result in faster symptom relief for distal disease, while systemic exposure remains low compared with oral formulations.

Mesalazine rectal formulations should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Mesalazine is supplied as a rectal preparation, such as an enema or suppository. The patient inserts the dose into the rectum according to the prescribing information, usually once or twice daily, allowing the drug to coat the colonic mucosa.

Serious adverse events, though rare, include severe allergic reactions (anaphylaxis, rash), significant gastrointestinal bleeding, hepatotoxicity, pancreatitis, and severe colitis. Patients should seek immediate medical attention if they experience any of these symptoms.

Mesalazine is contraindicated in individuals with known hypersensitivity to mesalazine or any component of the formulation. Caution is also advised for patients with severe renal or hepatic impairment, and it should be avoided in those with active severe ulcerative colitis without close monitoring.